ÂÜÀòÂÒÂ×

Anders Fink V. currently serves as the Interim Chief Financial Officer at Minervax ApS while also holding a Non-Executive Director position at Amplify Therapeutics ApS. Since 2015, Fink has been involved with Alpha Healthcare Investments ApS and Fink Consult ApS as a Financial Services Consultant. Previously, Fink was the Chief Executive Officer of Orphazyme A/S, overseeing a successful in-court restructuring and asset sale, and held several key positions, including Chief Financial Officer and CEO at Topotarget A/S, leading the company to a significant FDA approval and subsequent merger. Fink's earlier experience includes roles at BankInvest, 7TM Pharma, Copenhagen Capacity, and Carnegie Investment Bank, complemented by a strong educational background from prestigious institutions such as Harvard Business School and Copenhagen Business School.